Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Apolipoprotein A-I (ApoA-I) Overview | 6 | 4 |
| Apolipoprotein A-I (ApoA-I) Products under Development by Stage of Development | 7 | 1 |
| Apolipoprotein A-I (ApoA-I) Products under Development by Therapy Area | 8 | 1 |
| Apolipoprotein A-I (ApoA-I) Products under Development by Indication | 9 | 1 |
| Apolipoprotein A-I (ApoA-I) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Apolipoprotein A-I (ApoA-I) Products under Development by Companies | 12 | 2 |
| Apolipoprotein A-I (ApoA-I) Products under Development by Universities/Institutes | 14 | 2 |
| Apolipoprotein A-I (ApoA-I) Therapeutics Assessment | 16 | 7 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 2 |
| Assessment by Route of Administration | 19 | 2 |
| Assessment by Molecule Type | 21 | 2 |
| Apolipoprotein A-I (ApoA-I) Companies Involved in Therapeutics Development | 23 | 5 |
| Arisaph Pharmaceuticals, Inc. | 23 | 1 |
| Cerenis Therapeutics Holding SA | 24 | 1 |
| CSL Limited | 25 | 1 |
| Esperion Therapeutics, Inc. | 26 | 1 |
| KineMed, Inc. | 27 | 1 |
| Apolipoprotein A-I (ApoA-I) Drug Profiles | 28 | 10 |
| 4-WF Drug Profile | 28 | 1 |
| ARI-1778 Drug Profile | 29 | 1 |
| CER-001 Drug Profile | 30 | 4 |
| CSL-112 Drug Profile | 34 | 2 |
| D-4F Drug Profile | 36 | 1 |
| KM-011 Drug Profile | 37 | 1 |
| Apolipoprotein A-I (ApoA-I) Dormant Projects | 38 | 1 |
| Apolipoprotein A-I (ApoA-I) Discontinued Products | 39 | 1 |
| Apolipoprotein A-I (ApoA-I) Featured News &Press Releases | 40 | 14 |
| Jun 02, 2016: Publication of the LOCATION Clinical Study Results in the Renowned Scientific Journal of the European Atherosclerosis Society (EAS) | 40 | 1 |
| Jan 28, 2016: Catalent Biologics And Cerenis Therapeutics Announce Phase III Trial Of CER-001 In Europe And North America Leveraging GPEx Cell Line Technology | 41 | 1 |
| Nov 10, 2015: Cerenis Therapeutics: New Data for CER-001 Presented in Key Oral Session at American Heart Association Conference 2015 | 41 | 1 |
| Sep 08, 2015: First patients enter phase II CARAT trial to assess reduction in atherosclerotic plaque using CER-001 in post Acute Coronary Syndrome (ACS) patients | 42 | 1 |
| Jul 15, 2015: Cerenis Therapeutics Announces the Results of the LOCATION Study | 43 | 1 |
| Nov 18, 2014: CSL112 Found to Elevate Cholesterol Efflux in Patients with Coronary Artery Disease and Mechanism for Rapid Cholesterol Efflux Capacity Demonstrated | 44 | 1 |
| Nov 12, 2014: CSL Launches AEGIS-I, a Phase 2b Clinical Study of CSL112, a Novel Apolipoprotein A-I Infusion Therapy Designed to Rapidly Remove Cholesterol from Arteries and Stabilize Plaque | 45 | 1 |
| Sep 03, 2014: Cerenis Receives EMA Orphan Drug Designations for CER-001 for the Treatment of ApoA-I and ABCA-1 Deficiencies | 46 | 1 |
| Jun 02, 2014: Cerenis Reports Two Positive Phase II Studies for HDL Mimetic CER-001 at EAS | 47 | 1 |
| Jan 02, 2014: Cerenis Reports Top-Line Phase II Results for its HDL Mimetic CER-001 | 48 | 1 |
| Nov 21, 2013: CSL releases positive data for potential new heart attack therapy and announces next phase of clinical development | 49 | 1 |
| Nov 05, 2012: Novel Apolipoprotein A-I Therapy, CSL112, May Represent New Option For Reducing Recurrent Heart Attack Risk, Early CSL Studies Show | 50 | 1 |
| Mar 15, 2011: Cerenis Initiates Phase II Study Of CER-001 In Acute Coronary Syndrome | 51 | 1 |
| Jul 26, 2010: Cerenis And Novasep Receive EUR10.7 Million Funding From French Government For Development Of CER-001 | 52 | 1 |
| May 18, 2010: Cerenis Reports Positive Results From Phase I Study Of CER-001 For Treatment Of Cardiovascular Disease | 53 | 1 |
| Appendix | 54 | 2 |
| Methodology | 54 | 1 |
| Coverage | 54 | 1 |
| Secondary Research | 54 | 1 |
| Primary Research | 54 | 1 |
| Expert Panel Validation | 54 | 1 |
| Contact Us | 54 | 1 |
| Disclaimer | 55 | 1 |